DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Neubig RR, Spedding M, Kenakin T, Christopoulos A.
International Union of Pharmacology Committee on Receptor
Nomenclature and Drug Classification. XXXVIII. Update on
terms and symbols in quantitative pharmacology. Pharmacol
Rev, 2003, 55:597–606.
Oberhauser V, Schwertfeger E, Rutz T, et al. Acetylcholine
release in human heart atrium: influence of muscarinic
autoreceptors, diabetes, and age. Circulation, 2001, 103:
1638–1643.
Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of
cevimeline on dry eye in patients with Sjögren’s syndrome: a
randomized, double-blind clinical study. Am J Ophthalmol,
2004, 138:6–17.
Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of
rhodopsin: A G protein–coupled receptor. Science, 2000,
289:739–745.
Porter SR, Scully C, Hegarty AM. An update of the etiology and
management of xerostomia. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod, 2004, 97:28–46.
Richelson E. Receptor pharmacology of neuroleptics: Relation to
clinical effects. J Clin Psychiatry, 1999, 10 (suppl 10):5–14.
Roth B, Sheffler DJ, Kroeze WK. Magic shotguns versus magic
bullets: selectively non-selective drugs for mood disorders and
schizophrenia. Nature Rev Drug Discov, 2004, 3:353–359.
Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic
receptor agonist xanomeline as a novel treatment approach for
schizophrenia. Am J Psychiatry, 2008, 165:1033–1039.
Stengel PW, Gomeza J, Wess J, Cohen ML. M 2
and M 4
receptor
knockout mice: muscarinic receptor function in cardiac and
smooth muscle in vitro. J Pharmacol Exp Ther, 2000,
292:877–885.
Trendelenburg AU, Meyer A, Wess J, Starke K. Distinct mixtures
of muscarinic receptor subtypes mediate inhibition of noradrenaline
release in different mouse peripheral tissues, as studied
with receptor knockout mice. Br J Pharmacol, 2005,
145:1153–1159.
Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis.
Drugs, 1997, 54:581–596.
Valant C, Gregory, KJ, Hall NE, et al. A novel mechanism of G
protein-coupled receptor functional selectivity. J Biol Chem,
2008, 283:29312–29321.
Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes
in cerebral cortex and hippocampus. Progr Brain Res,
2004, 145:59–66.
Wein AJ. Practical uropharmacology. Urol Clin North Am, 1991,
18:269–281.
Wellstein A, Pitschner HF. Complex dose-response curves of
atropine in man explained by different functions of M 1
- and
M 2
-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol,
1988, 338:19–27.
Wess J. Molecular biology of muscarinic acetylcholine receptors.
Crit Rev Neurobiol, 1996, 10:69–99.
Wess J. Muscarinic acetylcholine receptor knockout mice: novel
phenotypes and clinical implications. Annu. Rev. Pharmacol.
Toxicol., 2004, 44: 423–450.
Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors:
mutant mice provide new insights for drug development.
Nature Rev Drug Discov, 2007, 6:721–733.
Wiseman LR, Faulds D. Oral pilocarpine: A review of its pharmacological
properties and clinical potential in xerostomia.
Drugs, 1995, 49:143–155.
Yamada M, Lamping KG, Duttaroy A, et al. Cholinergic dilation
of cerebral blood vessels is abolished in M 5
muscarinic
acetylcholine receptor knockout mice. Proc Natl Acad Sci
USA, 2001a, 98:14096–14101.
Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M 3
muscarinic acetylcholine receptor are hypophagic and lean.
Nature, 2001b, 410:207–212.
237
CHAPTER 9
MUSCARINIC RECEPTOR AGONISTS AND ANTAGONISTS